Adial Announces Appointment of Tony Goodman as Chief Operating Officer
January 18, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
Charlottesville, Va., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
December 20, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
November 29, 2023 16:05 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 17:02 ET
|
Adial Pharmaceuticals, Inc
Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award ...
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
October 31, 2023 08:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar
October 25, 2023 08:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
October 24, 2023 16:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
October 20, 2023 08:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
October 19, 2023 10:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award
October 18, 2023 08:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...